drug_type
RELEVANT_DRUG
intervention_type
Cellular immunotherapy
drug_description
Autologous, ex vivo–expanded tumor-infiltrating lymphocyte (TIL) product composed of polyclonal T cells that recognize patient-specific tumor neoantigens via the TCR and mediate cytotoxicity (perforin/granzyme and IFN-γ).
nci_thesaurus_concept_id
C204173
nci_thesaurus_definition
A preparation of autologous tumor-infiltrating lymphocytes (TILs) derived from each patients resected tumor and edited with the clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) system to eliminate the expression of as of yet not elucidated immunoregulatory targets, with potential immunomodulating and antineoplastic activities. Upon administration back into the patient, autologous CRISPR-edited TILs GT316 specifically recognize and kill the patients tumor cells. The knockout of the immunoregulatory targets may enhance the proliferation and cytokine release of the TILs.
drug_mesh_term
Lymphocytes, Tumor-Infiltrating
drug_category
TUMOR INFILTRATING LYMPHOCYTES
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous, ex vivo–expanded polyclonal TILs that are CRISPR/Cas9-edited to remove immunoregulatory targets; they recognize patient-specific tumor neoantigens via TCR–HLA interactions and kill tumor cells through perforin/granzyme release and IFN-γ–mediated cytotoxicity, enhancing TIL proliferation and function.
drug_name
GT316
nct_id_drug_ref
NCT06145802